{
    "2019-02-04": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy",
                "features": {
                    "keywords": [
                        "Teva",
                        "Gains",
                        "Positive",
                        "CHMP",
                        "Opinion",
                        "Migraine",
                        "Drug",
                        "Ajovy"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-20",
                "original_text": "What's in the Cards for Glaxo (GSK) This Earnings Season?",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "GSK",
                        "Earnings",
                        "Season"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-10",
                "original_text": "Better Buy: Johnson & Johnson vs. Merck & Co.",
                "features": {
                    "keywords": [
                        "Better",
                        "Buy",
                        "Johnson",
                        "&",
                        "Johnson",
                        "vs.",
                        "Merck",
                        "&",
                        "Co."
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "Novartis Backs Lutathera Pricing After Price-Gouging Accusations",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Backs",
                        "Lutathera",
                        "Pricing",
                        "Price-Gouging",
                        "Accusations"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}